ATE275975T1 - Mikroverkapselte ngf zusammensetzungen mit geregelter freigabe - Google Patents

Mikroverkapselte ngf zusammensetzungen mit geregelter freigabe

Info

Publication number
ATE275975T1
ATE275975T1 AT98928902T AT98928902T ATE275975T1 AT E275975 T1 ATE275975 T1 AT E275975T1 AT 98928902 T AT98928902 T AT 98928902T AT 98928902 T AT98928902 T AT 98928902T AT E275975 T1 ATE275975 T1 AT E275975T1
Authority
AT
Austria
Prior art keywords
encapsuled
micro
regulated release
ngf compositions
ngf
Prior art date
Application number
AT98928902T
Other languages
English (en)
Inventor
Jeffrey L Cleland
Xanthe M Lam
Eileen T Duenas
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE275975T1 publication Critical patent/ATE275975T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98928902T 1997-06-13 1998-06-11 Mikroverkapselte ngf zusammensetzungen mit geregelter freigabe ATE275975T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/874,647 US6113947A (en) 1997-06-13 1997-06-13 Controlled release microencapsulated NGF formulation
PCT/US1998/011600 WO1998056426A1 (en) 1997-06-13 1998-06-11 Controlled release microencapsulated ngf formulation

Publications (1)

Publication Number Publication Date
ATE275975T1 true ATE275975T1 (de) 2004-10-15

Family

ID=25364245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98928902T ATE275975T1 (de) 1997-06-13 1998-06-11 Mikroverkapselte ngf zusammensetzungen mit geregelter freigabe

Country Status (12)

Country Link
US (1) US6113947A (de)
EP (1) EP1001814B1 (de)
JP (1) JP4316682B2 (de)
AR (1) AR012978A1 (de)
AT (1) ATE275975T1 (de)
AU (1) AU730612B2 (de)
CA (1) CA2293575C (de)
DE (1) DE69826289T2 (de)
ES (1) ES2227844T3 (de)
IL (1) IL133112A (de)
WO (1) WO1998056426A1 (de)
ZA (1) ZA985138B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6406719B1 (en) * 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9906882D0 (en) * 1999-03-25 1999-05-19 Novartis Ag Organic compounds
SE9903236D0 (sv) * 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
WO2001034178A2 (en) * 1999-11-05 2001-05-17 Board Of Regents, The University Of Texas System Methods and compositions for treatment of traumatic brain injury
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
CA2409190A1 (en) 2000-04-14 2001-10-25 The Uab Research Foundation Poliovirus replicons encoding therapeutic agents and uses thereof
US6992065B2 (en) 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
US6565888B1 (en) * 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
JP5160005B2 (ja) * 2000-12-28 2013-03-13 武田薬品工業株式会社 徐放性製剤
CA2433037C (en) 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
JP4861560B2 (ja) * 2001-02-19 2012-01-25 株式会社明治 糖尿病合併症治療剤
JP3836684B2 (ja) * 2001-02-19 2006-10-25 明治乳業株式会社 排尿障害治療剤
ATE427760T1 (de) * 2001-02-23 2009-04-15 Genentech Inc Erodierbare polymere zur injektion
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
JP4460892B2 (ja) * 2001-06-21 2010-05-12 ジェネンテック インコーポレイテッド 徐放性組成物
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
WO2003068805A2 (en) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
US20040105821A1 (en) * 2002-09-30 2004-06-03 Howard Bernstein Sustained release pharmaceutical formulation for inhalation
WO2004035762A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
DK1610822T4 (en) * 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
DE10315640A1 (de) * 2003-04-04 2004-10-14 Ignatov, Konstantin Verfahren zur kontrollierten Freisetzung von Komponenten in eine Lösung
ES2600554T3 (es) * 2003-07-18 2017-02-09 Oakwood Laboratories L.L.C. Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
US7205387B2 (en) * 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
CN1856296A (zh) * 2003-09-30 2006-11-01 阿库斯菲尔公司 可注射的、口服、或局部用缓释药物制剂
US7090433B2 (en) * 2003-10-07 2006-08-15 Steve Searby Underground cable laying apparatus
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
US8617613B2 (en) 2004-04-15 2013-12-31 Alkermes Pharma Ireland Limited Polymer-based sustained release device
WO2005122734A2 (en) * 2004-06-14 2005-12-29 The Research Foundation Of State University Of New York Nanosphere/microsphere delivery system for the treatment of spinal cord injury
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006099739A1 (en) * 2005-03-23 2006-09-28 Ramot At Tel-Aviv University Ltd. Use of adnf polypeptides for treating peripheral neurotoxicity
US8067369B2 (en) * 2006-02-24 2011-11-29 Ramot At Tel-Aviv University Protection of the retina against laser injury by NAP and related peptides
EP2359808B1 (de) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotisches Verabreichungssystem mit Kolbenanordnung
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
US8800383B2 (en) 2009-08-24 2014-08-12 Particle Measuring Systems, Inc. Flow monitored particle sensor
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
EP2778221B1 (de) 2011-02-07 2017-07-26 Life Technologies Corporation Zusammensetzungen und Verfahren zur Stabilisierung von empfindlichen Verbindungen
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102488619B (zh) 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
US10983040B2 (en) 2013-03-15 2021-04-20 Particles Plus, Inc. Particle counter with integrated bootloader
US11579072B2 (en) 2013-03-15 2023-02-14 Particles Plus, Inc. Personal air quality monitoring system
US10352844B2 (en) 2013-03-15 2019-07-16 Particles Plus, Inc. Multiple particle sensors in a particle counter
US12044611B2 (en) 2013-03-15 2024-07-23 Particles Plus, Inc. Particle counter with integrated bootloader
US9677990B2 (en) 2014-04-30 2017-06-13 Particles Plus, Inc. Particle counter with advanced features
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
US10835604B2 (en) * 2015-08-13 2020-11-17 Northeastern University Biomaterials for combined radiotherapy and immunotherapy of cancer
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
KR102228571B1 (ko) * 2017-02-09 2021-03-16 주식회사 메디폴리머 정신질환 또는 중추신경계 질환 치료용 약물전달 제형
EP3406259A1 (de) * 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophine zur verwendung bei der behandlung von hörverlust
CN110090293B (zh) * 2019-05-10 2023-04-07 南京工业大学 一种抑制plga微球中多肽类药物酰化副反应的方法
US11988591B2 (en) 2020-07-01 2024-05-21 Particles Plus, Inc. Modular optical particle counter sensor and apparatus

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) * 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) * 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) * 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US5169762A (en) * 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3483949D1 (de) * 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
DE3474511D1 (en) * 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP2504289B2 (ja) * 1990-05-21 1996-06-05 宇部興産株式会社 押出プレス用後面設備サブストレッチャのテ―ルストック
US5488099A (en) * 1992-03-06 1996-01-30 Persson, Deceased; Hakan B. Multifunctional chimeric neurotrophic factors
AU685784B2 (en) * 1993-02-23 1998-01-29 Genentech Inc. Excipient stabilization of polypeptides treated with organic solvents
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
PT831787E (pt) * 1995-06-07 2002-02-28 Alkermes Inc Composicao para libertacao sustentada da hormona de crescimento humano
WO1997017087A1 (en) * 1995-11-07 1997-05-15 Genentech, Inc. Stabilizing formulation for ngf

Also Published As

Publication number Publication date
IL133112A0 (en) 2001-03-19
AU730612B2 (en) 2001-03-08
JP2002505671A (ja) 2002-02-19
CA2293575C (en) 2009-01-06
US6113947A (en) 2000-09-05
IL133112A (en) 2004-09-27
EP1001814A1 (de) 2000-05-24
JP4316682B2 (ja) 2009-08-19
EP1001814B1 (de) 2004-09-15
AR012978A1 (es) 2000-11-22
WO1998056426A1 (en) 1998-12-17
ES2227844T3 (es) 2005-04-01
DE69826289T2 (de) 2005-09-22
CA2293575A1 (en) 1998-12-17
ZA985138B (en) 1999-12-13
DE69826289D1 (de) 2004-10-21
AU8059298A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
ATE275975T1 (de) Mikroverkapselte ngf zusammensetzungen mit geregelter freigabe
DK0922386T3 (da) Sammensætninger med reguleret frigivelse
ATE252386T1 (de) Galantamin-zusammensetzung mit gesteuerter freisetzung
DK0973746T3 (da) Substituerede 3-cyanoquinoliner
DE69506086D1 (de) Zusammensetzung mit gesteuerter freisetzung
ID25508A (id) Komposisi dematologis
DE69833249D1 (de) Harzzusammensetzung
DE69808366D1 (de) Dimmer
ID23250A (id) Komposisi paroksetin
DE59813487D1 (de) Substituierte 4-benzoyl-pyrazole
ID21906A (id) Komposisi adesif
NO993944L (no) Utlösermekanisme
DE69822559D1 (de) Siliconzusammensetzung
DE59807892D1 (de) Lastverstellvorrichtung
DE69812401D1 (de) Schnellkupplung
DK0960100T3 (da) Substituerede 4-benzoyl-pyrazoler
DE69813094D1 (de) Feuerhemmende harzzusammensetzung
DE69808009D1 (de) Pestizide Zusammensetzung
FI970798A0 (fi) List foer en avvattningsanordning i en pappersmaskin
DE59704877D1 (de) Mikrogalvanisch hergestelltes bauteil
DE59807877D1 (de) Substituierte 4-benzoyl-pyrazole
ID24079A (id) Aminoheteroksiklilamida tersubstitusi
FI973568A0 (fi) Foerfarande foer att foerhindra sintring i en virvelbaedd
DE59805803D1 (de) Lastverstellvorrichtung
FI972138A0 (fi) Returtraog i bestrykningsanordning

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1001814

Country of ref document: EP